Skip to main content

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Gastroenterology

Awarded By

NGM Biopharmaceuticals

Start Date

May 1, 2015

End Date

October 31, 2019
 

Administered By

Medicine, Gastroenterology

Awarded By

NGM Biopharmaceuticals

Start Date

May 1, 2015

End Date

October 31, 2019